Association of the Cylin D1 G870A Polymorphism with Laryngeal Cancer: Are they Really Related?

  • Verim, Aysegul (Department of Otorhinolaryngology/Head and Neck Surgery, Haydarpasa Numune Education and Research Hospital) ;
  • Ozkan, Nazli (Department of Molecular Medicine, Istanbul University Experimental Research Institute) ;
  • Turan, Saime (Department of Molecular Medicine, Istanbul University Experimental Research Institute) ;
  • Korkmaz, Gurbet (Department of Molecular Medicine, Istanbul University Experimental Research Institute) ;
  • Cacina, Canan (Department of Molecular Medicine, Istanbul University Experimental Research Institute) ;
  • Yaylim, Ilhan (Department of Molecular Medicine, Istanbul University Experimental Research Institute) ;
  • Isbir, Turgay (Multidiciplinary Molecular Medicine Department, Institute of Health Sciences, Yeditepe University)
  • Published : 2013.12.31


Background: Cylin D1(CCDN1) is an important regulator of the cell cycle whose alterations are thought to be involved in cancer development. There have been many studies indicating CCDN1 amplification or over-expression in a variety of cancer types. In addition to gene amplification, the G870A polymorphism may be related with altered CCDN1 activity, and therefore with cancer development. This hypothesis has been tested in different cancer types but results have been contradictory. We therefore aimed to investigate any relationship between CCDN1 A870G genotypes and laryngeal squamous cell cancer development and progression. Materials and Methods: A total of 68 Turkish patients with primary laryngeal squamous cell cancer and 133 healthy controls were enrolled. Polymerase chain reaction-restriction fragment length polymorphism analysis was used to determine the CCDN1 genotypes. Results: No significant association was detected between CCDN1 genotypes and laryngeal squamous cell cancer (LxSCCa) development. Similarly CCDN1 genotypes were not related to clinical parameters of Lx SCCa. However, there was a very significant association between CCDN1 G allele and presence of perineural invasion (p=0.003; OR: 1.464; CI% 1.073-1.999). CCDN1 G allele frequency was significantly higher in the individuals with perineural invasion (85.7%) when compared to those without (58.5%). The 2 patients who died of disease were both found to possess the GG genotype. Conclusions: These results pose a controversy in suggesting a protective role of the G allele against LxSCCa development and support the association of CCDN1 gene GG genotype with mortality in patients with LxSCCa.


  1. Nilsson M, Chow WH, Lindblad M, Ye W (2005). No association between gastroesophageal reflux and cancers of the larynx and pharynx. Cancer Epidemiol Biomarkers Prev, 14, 1194-7.
  2. Nishimoto IN, Pinheiro NA, Rogatto SR, et al (2004). Cyclin D1gene polymorphism as a risk factor for squamous cell carcinoma of the upper aerodigestive system in nonalcoholics. Oral Oncol, 40, 604-10.
  3. Pabalan N, Bapat B, Sung L, et al (2008). Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 17, 2773-81.
  4. Palmero I, Peters G (1996). Perturbation of cell cycle regulators in human cancer. Cancer Surv, 27, 351-67.
  5. Papadimitrakopoulou V, Izzo JG, Liu DD, et al (2009). Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res, 2, 14-21.
  6. Qiuling S, Yuxin Z, Suhua Z, et al (2003). Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis, 24, 1499-503.
  7. Rydzanicz M, Golusinski P, Mielcarek-Kuchta D, Golusinski W, Szyfter K (2006). Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx. Eur Arch Otorhinolaryngol, 263, 43-8.
  8. Sanyal S, Festa F, Sakano S, et al (2004). Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis, 25, 729-34.
  9. Sawa H, Ohshima TA, Ukita H, et al (1998). Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene, 16, 1701-12.
  10. Schernhammer ES, Tranah GJ, Giovannucci E et al (2006). Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma. Br J Cancer, 94, 928-34.
  11. Sherr CJ (1995). D-type cyclins. Trends Biochem Sci, 20, 187-90.
  12. Sherr CJ (1996). Cancer cell cycles. Science, 274, 1672-7.
  13. Shu XO, Moore DB, Cai Q, et al (2005). Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev, 14, 91-7.
  14. Simpson DJ, Fryer AA, Grossman AB, et al (2001). Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas. Carcinogenesis, 22, 1801-7.
  15. Solomon DA, Wang Y, Fox SR, et al (2003). Cyclin D1 splice variants.Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem, 278, 30339-47.
  16. Tuncer M, Ozgul N, Olcayto EO, Gultekin M, Erdin B (2009). Turkish Republic, Ministry of Health, National Cancer Control Department, National Cancer Programme, 2009-15.
  17. Wang R, Zhang JH, Li Y, et al (2003). The association of cyclin D1 (A870G) polymorphism with susceptibility to esophageal and cardiac cancer in north Chinese population. Zhonghua Yi Xue Za Zhi, 83, 1089-92.
  18. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al (2003). Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst, 95, 198-205.
  19. Jain M, Kumar S, Upadhyay R, et al (2007). Influence of apoptosis (BCL2,FAS), cell cycle (CCND1) and growth factor (EGF,EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. Cancer Biol Ther, 6, 1553-8.
  20. Jares P, Fernandez PL, Campo E, et al (1994). PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res, 54, 4813-7.
  21. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES (2006). Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene, 25, 1620-8.
  22. Koufman JA, Burke AJ (1997). The etiology and pathogenesis of laryngeal carcinoma. Otolaryngol Clin North Am, 30, 1-19.
  23. Krippl P, Langsenlehner U, Renner W, et al (2003). The 870G4A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat, 54, 165-8.
  24. Landis SH, Murray T, Bolden S, Wingo PA( 1998). Cancer statistics, CA Cancer J Clin, 48, 6-29.
  25. Matthias C, Branigan K, Jahnke V, et al (1998). Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res, 4, 2411-8.
  26. Matthias C, Jahnke V, Jones PW, et al (1999). Cyclin D1, glutathione S-transferase, and cytochrome P450 genotypes and outcome in patients with upper aerodigestive tract cancers: assessment of the importance of individual genes using multivariate analysis. Cancer Epidemiol Biomarkers Prev, 8, 815-23.
  27. Michalides R, van Veelen N, Hart A, et al (1995).Overexpression of cyclin D1 correlates with recurrence in a group of fortyseven operable squamous cell carcinomas of the head and neck. Cancer Res, 55, 975-8.
  28. Miller SA, Dykes DD, Polesky HF(1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16, 1215.
  29. Monteiro E, Varzim G, Pires AM, Teixeira M, Lopes C(2004). Cyclin D1 A870G polymorphism and amplification in laryngeal squamous cell carcinoma: implications of tumor localization and tobacco exposure. Cancer Detect Prev, 28, 237-43.
  30. Motokura T, Arnold A (1993). Cyclins and oncogenesis. Biochim Biophys Acta, 1155, 63-78.
  31. Muller D, Millon R, Velten M, et al (1997). Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: correlation with clinical outcome. Eur J Cancer, 33, 2203-10.
  32. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T (1995). Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol, 146, 1161-9.
  33. Berrino F (1999). WHO, IARC, Commision of the European Communities.Survival of Cancer Patients in Europe:The EUROCARE-2 study. IARC Sci Publ, 151, 1-572.
  34. Betticher DC, Thatcher N, Altermatt HJ, et al (1995). Alternate splicing produces a novel cyclin D1 transcript. Oncogene, 11, 1005-11.
  35. Betticher DC (1996). Cyclin D1, another molecule of the year? Ann Oncol, 7, 223-5.
  36. Boffetta P, Ye W, Adami HO, Mucci LA, et al (2001). Risk of cancers of the lung, head and neck in patients hospitalized for alcoholism in Sweden. Br J Cancer, 85, 678-82.
  37. Callender T, el-Naggar AK, Lee MS, et al (1994). PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer, 74, 152-8.<152::AID-CNCR2820740124>3.0.CO;2-K
  38. Cann CI, Fried MP, Rothman KJ (1985). Epidemiology of squamous cell cancer of the head and neck. Otolaryngo Clin North Am, 18, 367-88.
  39. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H (1993). Trends in cancer incidence and mortality. IARC Sci Publ, 121, 1-806.
  40. Dhar KK, Branigan K, Howells RE, et al (1999). Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer. Int J Gynecol Cancer, 9, 342-7.
  41. Gazioglu NM, Erensoy N, Kadioglu P, Sayitoglu MA, Ersoy IH (2007). Altered cyclin D1 genotype distribution in human sporadic pituitary adenomas. Med Sci Monit, 13, 457-63.
  42. Gleich LL, Salamone FN (2002). Molecular genetics of head and neck cancer. Cancer Control, 9, 369-78.
  43. Grieu F, Malaney S, Ward R, Joseph D, Iacopetta B (2003). Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res, 23, 4257-9.
  44. Hall M, Peters G (1996). Genetic alterations of cyclins, cyclindependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res, 68, 67-108.
  45. Hibberts NA, Simpson DJ, Bicknell JE, et al (1999). Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res, 5, 2133-9.
  46. Huang SF, Cheng SD, Chuang WY, et al (2012). Cyclin D1 overexpression and poor clinical outcomes in Taiwanese oral cavity squamous cell carcinoma. World J Surg Oncol, 10, 40.
  47. Akervall JA, Michalides RJ, Mineta H, et al (1997). Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer, 79, 380-9.<380::AID-CNCR22>3.0.CO;2-W
  48. Bellacosa A, Almadori G, Cavallo S, et al (1996). Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res, 2, 175-80.
  49. Hunter T, Pines J (1994). Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell, 79, 573-82.
  50. Weinstein IB, Begemann M, Zhou P, et al (1997). Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res, 3, 2696-702.
  51. Yaylim-Eraltan I, Ergen A, Gormus U, et al (2009). Breast cancer and cyclin D1 gene polymorphism in Turkish women. In Vivo, 23, 767-72.
  52. Yilmaz T,Hosal AS,Gedikoglu Getal (1998).Prognostic significance of vascular and perineural invasion in cancer of the larynx. Am J Otolaryngol. 19, 83-8.
  53. Zhang LQ, Huang XE, Wang J, et al (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  54. Zhang J, Li Y, Wang R, et al (2003). Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer, 105, 281-4.
  55. Zheng Y, Shen H, Sturgis EM, et al (2001). Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis, 22, 1195-99.
  56. Zhuo W, Zhang L, Wang Y, Zhu B, Chen Z (2012). Cyclin D1 G870A polymorphism is a risk factor for esophageal cancer among Asians. Cancer Invest, 30, 630-6.

Cited by

  1. The Polymorphism of CYP2E1 Rsa I/Pst I Gene and Susceptibility to Respiratory System Cancer vol.93, pp.27, 2014,